TheraRadar

Esperion

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 8/4/2023

23
Total Trials
7
Phase 3
12
Phase 2
0
Recruiting
210
Score

Pipeline by Phase

Phase 3
7
Phase 2
12
Phase 1
3

Therapeutic Focus

Hypercholesterolemia Statin Adverse Reaction Atherosclerotic Cardiovascular Disease Hyperlipidemia Healthy Lactating Women

Clinical Trials (23)

NCT02993406 Phase 3 COMPLETED

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Started: 12/22/2016

NCT03067441 Phase 3 COMPLETED

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Started: 2/3/2017

NCT03001076 Phase 3 COMPLETED

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

Started: 11/29/2016

NCT02666664 Phase 3 COMPLETED

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

Started: 1/21/2016

NCT02991118 Phase 3 COMPLETED

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

Started: 11/18/2016

NCT03337308 Phase 3 COMPLETED

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Started: 10/23/2017

NCT02988115 Phase 3 COMPLETED

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

Started: 11/16/2016

NCT05694260 Phase 2 COMPLETED

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

Started: 1/12/2023

NCT02178098 Phase 2 COMPLETED

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

Started: 6/16/2014

NCT01751984 Phase 2 COMPLETED

A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

Started: 10/4/2012

NCT01262638 Phase 2 COMPLETED

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

Started: 12/1/2010

NCT03531905 Phase 2 COMPLETED

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Started: 5/9/2018

NCT03051100 Phase 2 COMPLETED

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Started: 1/19/2017

NCT03193047 Phase 2 COMPLETED

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Started: 4/7/2017

NCT01941836 Phase 2 COMPLETED

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

Started: 9/1/2013

NCT01779453 Phase 2 COMPLETED

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

Started: 12/1/2012

NCT02659397 Phase 2 COMPLETED

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

Started: 12/1/2015

NCT02072161 Phase 2 COMPLETED

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

Started: 3/1/2014

NCT01607294 Phase 2 COMPLETED

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

Started: 4/1/2012

NCT01485146 Phase 1 COMPLETED

A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects

Started: 10/25/2011

NCT01105598 Phase 1 COMPLETED

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

Started: 4/20/2010

NCT02044627 Phase 1 COMPLETED

Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002

Started: 12/1/2013

NCT06021951 Phase 4 COMPLETED

Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women

Started: 8/4/2023

Drug Candidates

Bempedoic acid Bempedoic Acid 180 MG Oral Tablet Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet Bempedoic acid 180 mg tablet Matching placebo tablet ETC-1002 Placebo bempedoic acid Ezetimibe placebo
Activity Status: Stale
Last Trial Started: 8/4/2023
Last Trial Ended: 6/4/2025
Trials (12 months): 0
Completed Trials: 23
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.